Oddity Tech Launches Methodiq Telehealth with 28 AI Skincare Products, 100 Plans

ODDODD

In November 2025 Oddity Tech launched Methodiq, a telehealth platform with 28 AI-powered skincare products and over 100 personalized treatment plans for acne, hyperpigmentation and eczema sufferers. Its direct-to-consumer data-driven model has boosted repeat-business rates, delivered a 73.1% gross margin and supports a $2.2 billion market cap poised for further expansion.

1. Breakout Potential in 2026

Oddity Tech has demonstrated the viability of its direct-to-consumer model through two established beauty brands, delivering cumulative annual revenue growth exceeding 75% since 2023. With five additional niche brands slated for launch by mid-2026—targeting segments such as clean hair care and men’s grooming—the company is positioned to expand its total addressable market from $45 billion to over $60 billion. Investors should note that Oddity’s customer acquisition cost has declined by 20% year-over-year, while its average order value has climbed 15%, signaling improved unit economics as new brands roll out.

2. Data-Driven Customer Flywheel

Oddity’s technology platform collects behavioral and purchase data across online and mobile channels, enabling real-time product assortment optimization and personalized marketing. Since implementing AI-driven recommendations in Q1 2025, the company reports a 30% lift in repeat purchase rates and a 25% reduction in churn among first-time buyers. Internal analysis shows that every dollar invested in data analytics returned $3.50 in incremental gross profit through targeted promotions and faster new-product validation cycles.

3. Methodiq Telehealth Launch

In November 2025, Oddity introduced Methodiq, a telehealth service addressing acne, hyperpigmentation and eczema with AI-powered skin diagnostics and 28 proprietary formulations developed by its Boston biotech subsidiary. Methodiq’s beta rollout has already attracted over 15,000 users, generating $1.2 million in subscription and product sales in the first two months. Management projects Methodiq to contribute 10% of total revenue by year-end 2026, tapping into a dermatology market estimated at $8 billion annually in the U.S.

4. Strategic Fit for Voyager Portfolio

The Voyager Portfolio’s decision to acquire Oddity shares reflects confidence in recurring revenue growth and high-margin expansion. With a current gross margin above 70% and operating leverage improving as customer acquisition costs fall, analysts foresee adjusted EBITDA doubling to $120 million in 2026. The portfolio manager highlights that Oddity’s success replicates consumer-tech winning patterns—high retention, scalable data infrastructure and rapid brand proliferation—offering a potential total return exceeding 50% over the next 18 months.

Sources

FZ